CClinicalTrials.gg
RecruitingNCT07760792Updated Sep 1, 2026

Risk Factors and Clinical Implications of Double-J Ureteral Stent Bacterial Colonization

An observational study in Bacterial Colonization and Double-J Ureteral Stents, sponsored by Al-Azhar University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Al-Azhar University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Study summary

This prospective cohort study will evaluate the risk factors associated with bacterial colonization of Double-J ureteral stents and examine its clinical implications. Adult patients undergoing temporary ureteral stent insertion for routine urological indications will be followed until stent removal, when urine and stent cultures will be obtained. The study will assess the association between colonization and factors such as indwelling time, diabetes mellitus, chronic kidney disease, prior urinary tract infection, prior antibiotic exposure, and stent-related symptoms.

Read the detailed description

This prospective observational cohort study will enroll adult patients undergoing temporary Double-J ureteral stent insertion at Al-Azhar University hospitals in Cairo, Egypt. Participants will be followed from stent insertion until removal. Baseline demographic, clinical, and laboratory data will be collected, together with stent-related variables such as stent side, size, material, and indwelling time. Midstream urine culture will be obtained when feasible before insertion and again at removal, and the stent will be cultured under sterile conditions at removal.

The primary outcome is bacterial colonization of the Double-J stent, defined as positive growth on stent culture at removal. Secondary outcomes include positive urine culture, febrile urinary tract infection, concordance between urine and stent cultures, antimicrobial resistance patterns, stent-related symptom burden, and need for hospitalization or additional treatment. Risk factors for colonization will be analyzed using multivariable logistic regression.

02

Conditions studied

  • Bacterial Colonization
  • Double-J Ureteral Stents
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Adults with temporary Double-J ureteral stents placed for routine urological indications and available for follow-up until stent removal.

Inclusion criteria

  • Age 18 years or older.
  • Temporary Double-J stent insertion.
  • Standard urological indication.
  • Planned stent removal during follow-up.
  • Ability to attend follow-up and provide specimens.
  • Written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Active urosepsis at insertion.
  • Permanent or intended long-term stenting.
  • Concomitant nephrostomy tube or urinary diversion.
  • Severe immunosuppression or neutropenia.
  • Incomplete baseline data.
  • Loss to follow-up or failure to retrieve the stent.
  • Refusal to participate.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Target follow-up
48 Weeks
Patient registry
Yes
05

What researchers measure

Primary outcomes

  1. Bacterial colonization of the Double-J ureteral stent

    Positive growth on stent culture at removal.

    Time frame: At the time of stent removal, assessed from 2 weeks up to 52 weeks after stent insertion.

Secondary outcomes

  1. Positive urine culture

    Positive midstream urine culture during stent indwelling or at removal.

    Time frame: From stent insertion until stent removal, assessed up to 52 weeks after insertion.

  2. Number of Participants With Febrile Urinary Tract Infection

    Development of urinary tract infection while the stent is in place; Confirmed by Clinical Assessment and Urine Culture

    Time frame: From stent insertion until stent removal, assessed up to 52 weeks after insertion.

  3. Agreement between urine culture and stent culture

    Agreement between urine culture and stent culture, assessed by Cohen's kappa coefficient

    Time frame: At stent removal, assessed from 2 weeks up to 52 weeks after stent insertion.

  4. Antimicrobial resistance profile

    Resistance pattern of organisms isolated from urine and stent cultures.

    Time frame: At stent removal, assessed from 2 weeks up to 52 weeks after stent insertion.

  5. Stent-related symptom burden

    Symptoms such as flank pain, dysuria, hematuria, frequency, and urgency, assessed by questionnaire if available.

    Time frame: From stent insertion until stent removal, assessed up to 52 weeks after insertion.

  6. Hospitalization or additional intervention

    Need for emergency visit, admission, or additional treatment related to stent-associated complications.

    Time frame: From stent insertion until stent removal, assessed up to 52 weeks after insertion.

06

Study locations

1 of 1 sites recruiting
  • Department of Urology, Al-Hussein and Sayed Galal University Hospitals, Al-Azhar University
    Cairo, Cairo Governorate 11633, Egypt
    • Abul-fotouh Ahmed, MD · Contact · abulfotouhahmed@yahoo.com · +201001066756
    • Mahmoud M Abdelmalik · Sub investigator
    • Ahmed AlRefae, MD · Sub investigator
    • Ibrahim Tagreda, MD · Sub investigator
    Recruiting
07

Registry details

Key details

Study ID
NCT07760792
Lead sponsor
Al-Azhar University
Responsible party
Abul-fotouh Ahmed (Professor of Urology, Al-Azhar University) — Principal investigator
First posted
Aug 12, 2026
Start date
Aug 10, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Sep 1, 2026

Study contacts

Abul-fotouh Ahmed, MD
Contact
abulfotouhahmed@yahoo.com
00201001066756
Abul-fotouh Ahmed, MD
principal investigator · Al-Azhar University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion